View Older Stories View More Recent Stories

Jun 11, 2018 08:00AM Paratek Presents New Analysis from Combined Phase 3 Skin Infection Studies Highlighting Efficacy of Omadacycline in Treating Drug Resistant S. aureus at ASM Microbe 2018
Jun 7, 2018 04:05PM Paratek Demonstrates Breadth of Omadacycline Clinical and Microbiological Data at ASM Microbe 2018
Jun 1, 2018 04:30PM Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
May 22, 2018 04:05PM Paratek Pharmaceuticals (PRTK) Reports New Analysis Highlighting Efficacy of Omadacycline in Treating Community-Acquired Bacterial Pneumonia
May 22, 2018 04:01PM Paratek Presents New Analysis Highlighting Efficacy of Omadacycline in Treating Community-Acquired Bacterial Pneumonia by Measures of Disease Severity
May 9, 2018 07:30AM Paratek Pharmaceuticals Reports First Quarter 2018 Financial Results
May 1, 2018 04:01PM Paratek Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Apr 25, 2018 05:03PM Paratek Pharmaceuticals to Report First Quarter 2018 Financial Results on May 9, 2018
Apr 23, 2018 07:37AM Paratek Pharmaceuticals (PRTK) Announces Data from Phase 3 OPTIC Study of Omadacycline versus Moxifloxacin
Apr 23, 2018 07:30AM Paratek Pharmaceuticals Presents New Microbiology Efficacy Data of Oral-only Omadacycline Against the Most Common Pathogens Associated with Skin Infections
Apr 23, 2018 07:30AM Paratek Pharmaceuticals Presents Data Supporting Potential Approval of Omadacycline for Treatment of Community-Acquired Bacterial Pneumonia Based on the EMA Guidelines at ECCMID
Apr 13, 2018 04:46PM Paratek Pharmaceuticals (PRTK) Names Rolf K. Hoffman to Board
Apr 13, 2018 04:40PM Paratek Appoints Rolf K. Hoffman to Company’s Board of Directors
Apr 12, 2018 07:30AM Paratek Pharmaceuticals Presenting New Data from Omadacycline Development Program at ECCMID 2018
Apr 4, 2018 04:02PM Paratek's (PRTK) NDA for Oral and Intravenous Omadacycline Accepted for Priority Review by FDA
Apr 4, 2018 04:01PM Paratek’s New Drug Applications for Oral and Intravenous Omadacycline Accepted for Priority Review by FDA
Mar 30, 2018 08:00AM Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Mar 28, 2018 08:00AM Paratek Pharmaceuticals to Present at the H.C. Wainwright Annual Global Life Sciences Conference
Mar 16, 2018 08:00AM Paratek Pharmaceuticals to Present at the 17th Annual Needham Healthcare Conference
Mar 2, 2018 08:00AM Paratek Pharmaceuticals to Present at the 38th Annual Cowen & Co. Health Care Conference
Mar 1, 2018 04:05PM Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Mar 1, 2018 07:00AM Paratek Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Remains on Track for Commercial Launch by First Quarter 2019
Feb 15, 2018 08:00AM Paratek Pharmaceuticals to Report Fourth Quarter and Full Year 2017 Financial Results on March 1, 2018
Feb 5, 2018 07:34AM Paratek (PRTK) Completes Submission of NDA for Oral and Intravenous Omadacycline for Pneumonia and Skin Infections
Feb 5, 2018 07:30AM Paratek Completes Submission of New Drug Applications to U.S. Food and Drug Administration for Oral and Intravenous Omadacycline for Pneumonia and Skin Infections
Feb 1, 2018 04:01PM Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Jan 31, 2018 08:00AM Paratek Pharmaceuticals to Present at LEERINK Partners 7th Annual Global Healthcare Conference
Jan 3, 2018 07:07AM Paratek Pharmaceuticals (PRTK) Provides Pipeline Update
Jan 3, 2018 07:00AM Paratek Provides Update on Pipeline Progress
Dec 20, 2017 04:31PM Allergan (AGN) and Paratek (PRTK) Report FDA Accepted NDA For Seysara for Treatment of Moderate to Severe Acne
Dec 20, 2017 04:30PM FDA Accepts New Drug Application For Seysara™ (Sarecycline) For The Treatment Of Moderate To Severe Acne
Dec 1, 2017 04:01PM Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Nov 8, 2017 07:00AM Paratek Pharmaceuticals Reports Third Quarter 2017 Financial Results, Remains on Track to Complete NDA Submissions in First Quarter of 2018
Nov 1, 2017 04:01PM Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Oct 24, 2017 04:01PM Paratek Pharmaceuticals to Report Third Quarter 2017 Financial Results and Provide Update on Clinical Progress on November 8, 2017
Oct 6, 2017 08:05AM Paratek Pharmaceuticals (PRTK) Reports Consistent Efficacy & Safety Profile Observed in New Analyses of OASIS-1 Phase 3 Study of Omadacycline
Oct 6, 2017 08:04AM Paratek Pharmaceuticals (PRTK) Says Phase 3 Optic Study Microbiology Data Shows Omadacycline has Potent In vitro Activity Against Multiple Pneumonia Pathogens
Oct 6, 2017 08:01AM Phase 3 Optic Study Microbiology Data Demonstrate Omadacycline has Potent In vitro Activity Against Multiple Pneumonia Pathogens, Including Resistant Bacteria
Oct 6, 2017 08:00AM Consistent Efficacy and Safety Profile Observed in New Analyses of OASIS-1 Phase 3 Study of Omadacycline in Patients with Difficult to Treat Comorbid Conditions
Oct 2, 2017 04:01PM Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Sep 25, 2017 08:00AM Paratek Pharmaceuticals to Present New Omadacycline Data at IDWeek 2017
Sep 21, 2017 08:03AM Paratek (PRTK) Says Omadacycline Received Qualified Infectious Disease Product Designation from FDA for Additional Indication
Sep 21, 2017 08:00AM Omadacycline Receives Qualified Infectious Disease Product Designation from FDA for an Additional Indication in Uncomplicated Urinary Tract Infections
Sep 19, 2017 04:01PM Paratek Pharmaceuticals, Inc. to Host Investor Day on October 17, 2017
Sep 1, 2017 04:01PM Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Aug 22, 2017 08:00AM Paratek Pharmaceuticals, Inc. to Present at Upcoming Investor Conferences
Aug 8, 2017 08:00AM Paratek Pharmaceuticals, Inc. to Present at Wedbush PacGrow Healthcare Conference
Aug 2, 2017 07:00AM Paratek Pharmaceuticals, Inc. Reports Second Quarter 2017 Financial Results and Provides Clinical Update
Oct 3, 2016 03:19PM Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) to Ring The Nasdaq Stock Market Closing Bell
View More Recent Stories View Older Stories